These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28052221)

  • 41. [Correlation between studies and general practice].
    MMW Fortschr Med; 2006 Nov; 148(46):49. PubMed ID: 17615791
    [No Abstract]   [Full Text] [Related]  

  • 42. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate.
    Schneider JP
    Geriatrics; 2006 Jan; 61(1):31-3. PubMed ID: 16405362
    [No Abstract]   [Full Text] [Related]  

  • 43. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?
    Saag KG
    Ann Rheum Dis; 2008 Oct; 67(10):1358-9. PubMed ID: 18791054
    [No Abstract]   [Full Text] [Related]  

  • 44. Future pharmaceutical research: the need to look beyond science.
    Seeger S
    Future Med Chem; 2014 May; 6(7):721-3. PubMed ID: 24941866
    [No Abstract]   [Full Text] [Related]  

  • 45. [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
    Palomo Atance E; Ballester Herrera MJ; Márquez de La Plata MA; Medina Cano E; Carmona Vilchez RM
    An Pediatr (Barc); 2011 Feb; 74(2):122-5. PubMed ID: 21169073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Alendronate and resorptive hypercalciuria].
    Arrabal-Polo MA; Arrabal-Martin M; Zuluaga-Gomez A
    Med Clin (Barc); 2011 Sep; 137(7):333. PubMed ID: 21543092
    [No Abstract]   [Full Text] [Related]  

  • 47. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Babb RR
    N Engl J Med; 2008 Mar; 358(12):1302-3; author reply 1303-4. PubMed ID: 18357641
    [No Abstract]   [Full Text] [Related]  

  • 48. [Alendronate for the prevention and treatment of postmenopausal osteoporosis. A survey of a Cochrane review].
    Eiken PA; Abrahamsen B
    Ugeskr Laeger; 2009 Mar; 171(11):903-6. PubMed ID: 19278615
    [No Abstract]   [Full Text] [Related]  

  • 49. Use of alendronate in the treatment of vitamin D intoxication in infants.
    Hatun S; Cizmecioğlu F
    Turk J Pediatr; 2005; 47(4):373-5. PubMed ID: 16363349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compliance with treatment for osteoporosis.
    Cooper A
    Lancet; 2006 Nov; 368(9548):1648. PubMed ID: 17098078
    [No Abstract]   [Full Text] [Related]  

  • 51. I was prescribed alendronate (Fosamax) for bone loss a year ago, when I was 55. I just got the results of my recent bone density scan and I'm puzzled by the results. Why would it show a good improvement in the spine but no so much on my hip? How long do I have to wait to see results on my bone density?
    Health News; 2006 May; 12(5):16. PubMed ID: 16685754
    [No Abstract]   [Full Text] [Related]  

  • 52. Use of alendronate after 5 years of treatment.
    Erviti J; Gorricho J
    JAMA; 2007 May; 297(18):1979; author reply 1980-1. PubMed ID: 17488959
    [No Abstract]   [Full Text] [Related]  

  • 53. Use of alendronate after 5 years of treatment.
    Ott SM
    JAMA; 2007 May; 297(18):1979; author reply 1980-1. PubMed ID: 17488958
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of alendronate after 5 years of treatment.
    Delmas PD
    JAMA; 2007 May; 297(18):1979-80; author reply 1980-1. PubMed ID: 17488957
    [No Abstract]   [Full Text] [Related]  

  • 55. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women.
    Sawka AM; Papaioannou A; Adachi JD; Gafni A; Hanley DA; Thabane L
    BMC Musculoskelet Disord; 2005 Jul; 6():39. PubMed ID: 16008835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection.
    Soejima M; Kawaguchi Y; Hara M; Saito S; Kamatani N; Yamanaka H
    J Rheumatol; 2008 Nov; 35(11):2284-6. PubMed ID: 19004061
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment.
    Fagerlund KM; Janckila AJ; Ylipahkala H; Tiitinen SL; Nenonen A; Cheng S; Uusi-Rasi K; Yam LT; Väänänen HK; Halleen JM
    Clin Lab; 2008; 54(9-10):347-54. PubMed ID: 19097492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmaceutical company trials and the integrity of medical research.
    Tritsmans L; Briscoe P; Lemmens P; Bussche GV
    Lancet; 1996 Jun; 347(9015):1628; author reply 1628-9. PubMed ID: 8667898
    [No Abstract]   [Full Text] [Related]  

  • 59. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 60. [Bone quality].
    Ito M
    Nihon Rinsho; 2009 May; 67(5):921-5. PubMed ID: 19432110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.